Because somapacitan is a large molecule that is poorly absorbed orally, it is not likely to reach the bloodstream of the infant or cause any adverse effects in breastfed infants. However, there is no published experience with somapacitan during breastfeeding, so an alternate drug may be preferred, especially while nursing a newborn or preterm infant.